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Background: Epigenetic modifications such as histone and DNA methylation are essential for silencing
pluripotency genes during embryonic stem cell (ESC) differentiation. G9a is the major histone H3 Lys9 (H3K9)
methyltransferase in euchromatin and is required for the de novo DNA methylation of the key regulator of
pluripotency Oct3/4 during ESC differentiation. Surprisingly, the catalytic activity of G9a is not required for its role in
de novo DNA methylation and the precise molecular mechanisms of G9a in this process are poorly understood. It
has been suggested that the G9a ankyrin repeat domain, which can interact with both H3K9me2 and the DNA
methyltransferase DNMT3A, could facilitate de novo DNA methylation by bridging the interaction between DNMT3A
and H3K9me2-marked chromatin.
Results: Here, we demonstrate that the G9a ankyrin domain H3K9me2-binding function is not required for the de novo
DNA methylation of Oct3/4 during ESC differentiation. Moreover, we show that the interaction between the G9a
ankyrin domain and DNMT3A is not sufficient to ensure efficient de novo DNA methylation. More importantly, we
characterize a specific residue of the G9a ankyrin domain (Asp905) that is critical for both maintaining cellular H3K9me2
levels in undifferentiated ESCs and for the establishment of de novo DNA methylation during differentiation.
Conclusions: These results represent an exciting breakthrough, which reveals 1) an unexpected critical biological
function of the G9a ankyrin domain in global histone H3K9 methylation and 2) valuable insights into the molecular
mechanisms and interaction surfaces through which G9a regulates de novo DNA methylation of Oct3/4 during ESC
differentiation.
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The remarkable property of embryonic stem cells (ESC)
to remain in a pluripotent state, poised to execute a
broad range of developmental programs, is due to fine
control of proper gene expression patterns by key regu-
lators of pluripotency such as the Oct3/4 and Nanog
transcription factors. This pluripotent state is charac-
terized by maintenance of transcriptionally permissive
chromatin, which underlies high genome plasticity from* Correspondence: daniellebittencourt@hotmail.com; stallcup@usc.edu
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article, unless otherwise stated.which other gene expression patterns are derived during
development [1-4]. Epigenetic modifications such as his-
tone and DNA methylation are essential for chromatin
reorganization during development, resulting in the silen-
cing of early embryonic genes and activation of lineage-
specific genes that drive differentiation in cell fates [5].
Underlining the importance of histone and DNA methy-
lation in the control of proper gene expression patterns in
ESCs, disruption of the G9a histone methyltransferase
gene in mice results in growth retardation and early
embryonic lethality due to deregulation of developmental
genes [6]. G9a-null ESCs display a dramatic reduction in
cellular mono- and dimethylated histone H3 lysine K9tral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
Bittencourt et al. Epigenetics & Chromatin 2014, 7:27 Page 2 of 12
http://www.epigeneticsandchromatin.com/content/7/1/27(H3K9) levels, indicating its role as the major histone
H3K9 methyltransferase. Furthermore, G9a-null ESCs
show deficient de novo DNA methylation of several early
embryonic genes, including Oct3/4 and Nanog during
differentiation [7-9], suggesting a key role of G9a in
establishing de novo DNA methylation. However, in con-
trast to histone methylation, the catalytic function of the
G9a C-terminal SET domain (Figure 1A, top panel) is not
required for its role in de novo DNA methylation [7,10].Figure 1 Characterization of mouse embryonic stem (ES) clonal
cell lines expressing G9a bearing point mutations in the cage
and non-cage residues of the ankyrin repeat (ANK) domain.
(A) Top panel: Diagram of full-length mG9a showing amino acid
sequence numbers and specific domains: E, Glu-rich; Cys, Cys-rich
ring finger-like; ANK, ankyrin repeat; SET, methyltransferase; and Pre
and Post, Cys-rich Pre-SET and post-SET. Bottom panel: Schematic
representation of the structural basis for ankyrin repeat (green)
recognition of dimethylated histone H3 Lysine 9 (gray). G9a residue
numbers are shown. H3K9me2 binds in a partial hydrophobic cage
composed of residues highlighted in red. Peptide binding is further
specified by the interaction of non-cage G9a residues (highlighted
in purple) with H3 Ser10, Thr11, Gly12 and Gly13. (B) Immunoblots
(IB) were performed on the indicated proteins (with GAPDH as
loading control) using whole cell extracts derived from wild-type
(TT2) mouse embryonic stem cells (mESCs), G9a-null mESCs (knock-out;
KO) or distinct clonal ESC lines (indicated by #1 and #2) stably
expressing wild-type G9a (+WT) or G9a harboring the indicated
point mutations in the ANK domain.A recent report has shown that the deletion of the G9a
central ankyrin repeat domain (ANK, Figure 1A, top panel)
results in impaired de novo DNA methylation of the Oct3/4
gene promoter during ESC differentiation [7]. Interest-
ingly, the G9a ANK domain also binds to the de novo
DNA methyltransferase DNMT3A in vitro [7], although it
has not yet been determined whether this interaction is
required and/or sufficient for G9a-mediated de novo DNA
methylation. Furthermore, the G9a ANK domain specific-
ally binds to the product of G9a catalytic activity: histone
H3 mono- or dimethylated at K9 [11]. Indeed, G9a binding
to K9-methylated histone H3 involves recognition of two
different features of the methylated histone by a discreet
region of the ANK domain, as previously demonstrated by
X-ray crystallography: 1) a partial hydrophobic cage of
ANK recognizes the dimethylamino moiety of H3K9me2,
and 2) a nearby non-cage functional surface of ANK inter-
acts with residues 10 to 13 of histone H3 [11] (Figure 1A,
bottom panel). However, the biological function of this
binding is not fully understood, and to date, the precise
molecular mechanisms by which G9a and, in particular its
ANK domain, contribute to de novo DNA methylation re-
main unclear.
To address these questions, we established clonal
ESC lines expressing G9a with point mutations in the
ANK domain that prevent K9-dimethylated histone H3
binding. With these cell lines, we investigated the role
of this histone H3 binding surface in regulating markers
of ESC differentiation, global cellular H3K9 methylation,
and de novo DNA methylation of the Oct3/4 gene pro-
moter both in undifferentiated ESCs and during retinoic
acid (RA)-induced differentiation. Our results reveal that
these three parameters of ESC biology have distinct re-
quirements for different surfaces of G9a. Surprisingly, we
found that different point mutations that disrupt ANK do-
main binding to K9-dimethylated histone H3 had different
phenotypes, suggesting that the histone H3 binding
surface of the ANK domain may have multiple functions
involving multiple interacting protein partners. We also
define a specific residue in the G9a ANK domain that
is critical for its role in de novo DNA methylation.
Altogether, our findings represent an exciting break-
through, which can reveal 1) novel biological functions of
the G9a ANK domain, and 2) valuable insights into the
mechanisms of the distinct functional surfaces of the G9a
ANK in supporting de novo DNA methylation, H3K9
methylation and ESC differentiation.
Results
Derivation of clonal embryonic stem cell lines expressing
G9a with point mutations in the ankyrin repeat domain
Our previous X-ray crystallography studies characterized
six residues of the G9a ankyrin repeat (ANK) domain
that are involved in G9a binding to the N-terminal tail
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While four of these residues (Trp839, Trp844, Glu847 and
Trp877) form a partial hydrophobic cage that interacts
with the dimethylamino moiety of H3K9me2 (Figure 1A,
bottom panel, highlighted in red), residues Glu870 and
D905 of the G9a ANK non-cage functional surface inter-
act with amino acids 10 to 13 of histone H3 [11]
(Figure 1A, bottom panel, highlighted in purple). A single
point mutation in any of these six G9a residues is suffi-
cient to disrupt the interaction in vitro between G9a and
a histone H3 N-terminal peptide dimethylated at K9.
Importantly, none of these mutations abolish G9a cata-
lytic function as determined by in vitro assays or its
structural integrity, as demonstrated by the ability of
the G9a ANK domain containing any of these muta-
tions to interact with protein partners GRIP1 and Gfi1
[11]. Thus, to date the biological function of the histone
H3 interacting surface of the G9a ANK domain is
unknown.
In order to investigate whether the methylhistone H3
binding function of the G9a ANK domain is required for
mESC differentiation and the accompanying de novo
DNA methylation of key pluripotency genes, G9a-nullFigure 2 G9a is not required for the transcriptional repression of sele
differentiation. The indicated mESC lines were untreated (0) or treated wi
determine G9a, Oct3/4 and GAPDH (loading control) protein levels in whol
indicated genes using RT-qPCR analysis with Ubiquitin C (UBC) as the norm
sample. Results shown are mean ± SD for three PCR reactions performed o
independent experiments.mESCs (knock-out; KO) were used to generate stable
clonal cell lines expressing either wild-type (+WT) G9a
or G9a containing various ANK domain point mutations
mentioned above. Importantly, two independent clones
expressing each G9a mutant were established in order to
control for potential clonal artifacts. Immunoblots were
performed to verify that the G9a expression level in
these cell lines is comparable to the endogenous G9a
expression in the wild-type parental mESC line TT2
(Figure 1B, top panel). Importantly, the protein expres-
sion levels of master regulators of pluripotency such as
Oct3/4, Sox2 and Nanog (Figure 1B), as well as of key
players in DNA methylation (DNA methyltransferases:
DNMT3A, DNMT3B and DNMT1), were also compar-
able in all undifferentiated ESC lines (Figure 1B). Im-
munoblots were repeated several times using different
protein extracts and slight differences observed in
protein expression levels between cell lines seen here
(Figure 1B) were not found consistently. Notably, messen-
ger RNA (mRNA) expression levels of early embryonic
genes (Oct3/4, Nanog, Klf4, Esrrb and Dppa3) deter-
mined by quantitative RT-qPCR were similar in all cell
lines (Figure 2B).cted early embryonic genes during retinoic acid (RA)-induced
th 1 μM RA for 2, 4 or 8 days. (A) Immunoblots were used to
e cell extracts. (B) Graph shows the messenger (mRNA) levels for the
alization control. All mRNA levels are normalized to the TT2 0 RA
n the same cDNA sample and are representative of three
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repeat domain is required for establishing de novo DNA
methylation during mouse embryonic stem cell
differentiation
Several reports demonstrate the requirement of G9a and
its ANK domain for proper de novo DNA methylation of
numerous early embryonic genes [6-8,12]. However, the
molecular mechanisms of G9a ANK domain function in
facilitating DNA methylation remain unknown. Using
the ESC clones expressing the G9a point mutants
described above, we investigated the role of the methyl-
histone binding surface of the G9a ANK domain in the
de novo DNA methylation of the Oct3/4 gene promoter
during ESC differentiation. Differentiation of stable ESCFigure 3 The G9a non-cage histone H3 binding surface of the ankyrin
of the Oct3/4 gene promoter during retinoic acid (RA)-induced embry
indicated mouse embryonic stem cell (mESC) lines, grown under self-renewal c
treated with sodium bisulfite, amplified using specific Oct3/4 promoter primers
CpG positions within the Oct3/4 gene promoter is shown. The methylation sta
to the transcription start site) was examined. (B) Percentage of DNA methylatio
clonal cell line is indicated in the table, which summarizes data shown in (C) a
(C) or treated with RA for 8 days (D) was treated with sodium bisulfite, amplifie
sequence analysis. Each horizontal row represents results from sequencing a se
indicated in parentheses beside the clone designation. The number of indepen
DNA clones (c) were derived is also indicated.lines expressing wild-type or mutant G9a was induced
by the addition of retinoic acid (RA) to the growth
medium. The DNA methylation status of the Oct3/4
proximal promoter region prior to and after 8 days of
RA treatment (Figure 3) was assessed by sequencing
PCR products generated from bisulfite-treated genomic
DNA. As expected, in undifferentiated mESCs, the Oct3/4
gene promoter is not methylated (Figures 3B and 3C).
In agreement with previous findings, mESCs expressing
either endogenous wild-type G9a (TT2) or exogenously
introduced wild-type G9a (+WT) underwent de novo
DNA methylation of the Oct3/4 promoter, with CpG
methylation levels of 46 to 58% in the region examined
after 8 days of RA treatment (Figures 3B and 3D, lowerrepeat (ANK) domain is required for de novo DNA methylation
onic stem cell (ESC) differentiation. DNA extracted from the
onditions or treated with RA for 8 days to induce differentiation, was
, cloned and subjected to sequence analysis. (A) Schematic diagram of
tus of eight CpG sites (no. 1 to 8) within the promoter (-90 to -258 relative
n for the Oct3/4 promoter region encompassing eight CpG sites of each
nd (D). DNA extracted from the indicated mESC lines that were untreated
d using specific Oct3/4 promoter primers, cloned and subjected to
parate DNA clone. The overall percentage of methylated CpG sites is
dent biological replicate experiments (n) from which the total number of
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of the G9a ankyrin domain that specifically recognize the
dimethylamino moiety of H3K9me2 (+W839A, +W877A
and + E847A) [11] did not compromise de novo DNA
methylation of Oct3/4 (Figure 3B and 3D). These results
suggest that G9a binding to histone H3 containing
mono- and dimethyl K9 is not required for de novo
DNA methylation. In contrast, mESCs expressing G9a
harboring a single point mutation of the Asp905 resi-
due located in a distinct non-cage surface of the ANK
domain that interacts with histone H3 residues 10 to 13
[11] display more than a twofold reduction in de novo
DNA methylation levels of Oct3/4, similar to the levels
observed in G9a-null mESCs (knock-out; KO) (Figure 3B
and 3D). Although some degree of clonal variability was
observed between the two W839A mutant clones, both
clones have higher DNA methylation levels after 8 days of
RA treatment compared to the KO and D905R. Therefore,
we can conclude that the W839A mutation does not im-
pair de novo DNA methylation of Oct4. In summary, these
results indicate that the cage and non-cage portions of the
dimethyl-histone H3 binding surface have common and
distinct functions, that is, binding of histone H3 contain-
ing dimethyl K9 and regulation of de novo DNA methyla-
tion, respectively.
The G9a ankyrin repeat domain, but not its histone-
binding surfaces, is required for the interaction between
G9a and DNMT3A
Previous studies have shown that the G9a ANK do-
main is required in vitro for binding between G9a and
DNMT3A [7]. We confirmed these findings via co-
immunoprecipitation of transiently transfected human
influenza hemagglutinin (HA) tagged full-length WT
or ΔANK mutant mouse G9a and full-length mouse
DNMT3A in a different cell line (COS-7 cell extracts)
(Figure 4B). Although the interaction with DNMT3a is
observed with WT G9a, it is abrogated in the G9a
ΔANK mutant (Figure 4B, left panel, lane 3). However,
the specific functional surface of the G9a ANK domain
responsible for this binding, as well as the physio-
logical relevance of this interaction for establishing de
novo DNA methylation, has not been defined. In order
to determine whether the impaired de novo DNA methyla-
tion observed in the D905R non-cage G9a ANK mutant
ESC lines is due to compromised interaction between
DNMT3A and the mutant G9a, co-immunoprecipitation of
transiently transfected FLAG-tagged full-length (WT or
mutant) mouse G9a and full-length mouse DNMT3A
was performed in COS-7 cell extracts. As expected, co-
immunoprecipitated DNMT3A was detected when
antibodies against FLAG were used for immunoprecipi-
tation of wild-type G9a (Figure 4A, left panel, lane 3).
Interestingly, none of the mutations in the G9a ANKdomain eliminated binding between G9a and DNMT3A
(Figure 4A, left panel lane 3). Anti-FLAG and Anti-G9a
immunoblots on the same samples (Figure 4A, right
and middle panels, respectively) are shown as a control
for G9a immunoprecipitation. Although the efficiency
of DNMT3A co-precipitation varied among the clones,
the pattern of variation did not correlate with the ob-
served DNA methylation of the Oct3/4 promoter; that
is, DNMT3A co-precipitation with the D905R mutant
(which has reduced DNA methylation of Oct3/4) is
equal to or better than that for several of the other mutants
(which support wild-type DNA methylation of Oct3/4).
These results suggest that G9a binding to DNMT3A via
the G9a ANK domain does not involve the ANK his-
tone H3 binding surface but rather a different part of
the ANK domain. More importantly, these data show
that, although G9a and DNMT3A interaction is main-
tained in the D905R non-cage ANK mutant, this inter-
action is not sufficient to ensure proper de novo DNA
methylation and a non-redundant function of the non-
cage surface of the ANK H3 binding domain is critical
to this process.
The G9a non-cage ankyrin repeat domain histone-binding
surface is required to maintain global cellular H3K9me2
levels
The G9a C-terminal SET catalytic domain is respon-
sible for its H3K9 methyltransferase activity [13]. As
shown previously [6], we found that global H3K9me2
levels were dramatically decreased upon G9a depletion
(Figure 4C, lane 2). However, these levels in mESCs
were not affected by mutations in the G9a ankyrin
cage domain (Figure 4C, lanes 7 to 11). Surprisingly, a
dramatic decrease in H3K9me2 levels was observed in
mESCs harboring the G9aD905R mutation in the non-
cage histone H3 binding surface of the ANK domain
(Figure 4C, lanes 5 and 6). The H3K9me2 level was
similar in cells expressing G9aD905R or lacking G9a
altogether, despite the fact that the G9a D905R mutant
is not catalytically dead when assayed in vitro [11]. It
is well known that G9a exerts its histone methyltrans-
ferase activity in a heterodimeric complex with the
G9a-like protein GLP [14]. In order to rule out the
possibility that the impaired histone methylation ob-
served in mESCs expressing G9aD905R (Figure 4C,
lanes 5 and 6) was due to the fact that the D905R
mutation in the G9a ANK domain abrogates the inter-
action between G9a and GLP, co-immunoprecipitation
of transiently transfected FLAG-tagged full-length
(WT or D905R mutant) mouse G9a and HA-tagged
full-length mouse GLP was performed in COS-7 cell
extracts. Co-immunoprecipitated GLP was detected
when antibodies against FLAG were used for immuno-
precipitation of wild-type G9a (Figure 4D, left panel,
Figure 4 Mutations in the histone H3 binding surface of the G9a ankyrin repeat (ANK) domain do not abrogate binding to DNMT3A.
COS- 7 cells were transiently transfected with pcDNA3.1-mDNMT3A (A and B) or pSG5-HA-mGLP full-length (D) and pSG5-FLAG-mG9a full-length
(A, B and D) or pSG5-HA-mG9a.ΔANK (B). G9a was either wild-type (WT) or contained the indicated point mutations in the ANK domain. G9a, GLP
and DNMT3A were immunoprecipitated from cell extracts with an anti-FLAG/anti-HA, anti-HA or anti-DNMT3A antibody, respectively. Non-immune
IgG antibody was used for immunoprecipitation background estimation. Bound proteins were analyzed by immunoblot (IB) with the indicated
antibodies. A 1% input sample was loaded for comparison. High (3 minutes) and low (1 minute) exposure times are shown (B). (C) Immunoblots were
used to determine H3K9me2 and H3 protein levels in acid histone extracts from the indicated undifferentiated mESC lines.
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GLP is not abrogated by the D905R mutation in the
G9a ANK domain. Altogether, these findings reveal a
novel role of the G9a ANK domain in global histone
H3K9 methylation and support the hypothesis where
the Asp905 residue of the G9a ANK domain non-cage
histone H3 binding surface can potentially contribute
to H3 substrate recognition by the SET domain.G9a, but not its ankyrin repeat histone binding surface, is
required for the silencing of the embryonic stem cell-
specific SSEA-1 surface marker during differentiation
Since G9a depletion or mutation of the G9a D905 ANK
non-cage residue results in deficient de novo DNA methy-
lation of Oct3/4 during mESC differentiation, we further
investigated whether this was accompanied by impaired
transcriptional repression of Oct3/4 in response to RA
Figure 5 G9a, but not the histone H3 binding surface of the
ankyrin repeat (ANK) domain, is required for efficient
repression of SSEA-1 expression during embryonic stem cell
(ESC) differentiation induced by retinoic acid (RA). Fluorescence-
activated cell sorting (FACS) analysis of cell surface protein SSEA-1
expression in the indicated mESC lines that were untreated (0) or
treated with RA for 3 or 7 days. Shaded histograms show nonspecific
staining (obtained when staining exclusively with secondary antibody)
and open histograms show specific SSEA-1 staining (staining with both
primary and secondary antibodies).
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immunoblot analysis with an antibody against Oct3/4
protein using whole cell extracts derived from mESCs
that were treated with RA for the indicated number of
days (Figure 2A). Interestingly, the combined defects in
both global H3K9 methylation levels and de novo DNA
methylation observed in the G9a-null and G9a D905R
mutant mESCs do not result in impaired repression of
Oct3/4 protein expression in response to RA treatment
(Figure 2A). Although the G9a protein levels appear to
decrease after 8 days of RA treatment for the D905R
mutant but not for the TT2 control (Figure 2A), this
difference was not observed in repeat experiments. We
further monitored by quantitative real-time PCR the
expression of the Oct3/4, Nanog, Klf4, Dppa3 and Esrrb
early embryonic genes during mESC differentiation
(Figure 2B). All WT, G9a knock-out and ANK mutant
stable ESC lines displayed comparable mRNA levels of
the above genes prior to RA treatment and the mRNA
levels of these genes was similarly decreased in
response to RA in all cell lines (Figure 2B). Altogether,
these data show that G9a is not required for the transcrip-
tional repression of several early embryonic genes in re-
sponse to RA. The discrepancy between G9a protein levels
(Figure 1B) which appear comparable amongst the parental
TT2 and the constructed cell lines and G9a mRNA levels
(Figure 2B), which are 50% lower in constructed cell lines
compared to the parental cell line TT2 is due to the fact
that the primers used to quantify G9a mRNA detect both
G9a long and short isoforms which are both expressed at a
1:1 ratio in the TT2 cell line while cell lines constructed for
the purpose of this study express solely the G9a long
isoform (Figure 1B upper panel: 2 bands in TT2 lane in
contrast to 1 band for all other constructed cell lines).
The levels of the ESC-specific cell-surface marker SSEA-1
have been shown to inversely correlate with the degree of
ESC differentiation. By flow cytometry, we observed that
WT TT2 mESCs show high expression of SSEA-1 prior to
RA treatment, and that these levels gradually decrease to
background levels 7 days after the onset of RA treat-
ment, as expected due to ESC differentiation (Figure 5).
In contrast, G9a-null mESCs still retain partial SSEA-1
expression even 7 days after the onset of RA treatment,
consistent with differentiation defects that have been
attributed to the lack of G9a [15]. These results are in
agreement with previous findings that G9a is essential
for development and differentiation [16]. Interestingly,
re-expression of WT as well as ankyrin cage and non-cage
mutants of G9a rescued the impaired repression of SSEA-1
expression observed in the G9a-null ESCs (Figure 5). In-
deed, all ESC lines analyzed, except the G9a-null line,
show high expression of SSEA-1 prior to RA treatment
and these levels gradually decrease to background levels 7
days after the onset of RA treatment. Altogether, these
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the histone H3 interaction surface of its ANK domain
are required for shutting down expression of SSEA-1. In
addition, the results indicate that G9a is only required for
repression of a subset of the ESC genes that are turned off
during the differentiation process.
Discussion
Distinct roles for the cage and non-cage regions of the
G9a ankyrin repeat surface that binds K9-methylated
histone H3
Our previous study demonstrated that the G9a ANK
domain binds preferentially to histone H3 when it is
modified by mono- or dimethylation at K9. In addition,
we demonstrated that all of the ANK point mutations
tested here disrupt binding to K9-monomethylated
or -dimethylated histone H3. These mutations therefore
defined a binding surface for histone H3 mono- or
dimethylated at K9. The X-ray crystal structure indicated
that the binding surface consists of a partial hydrophobic
cage that encloses the dimethylamino moiety of the K9
residue of histone H3, and a surface outside of that cage
that interacts with histone H3 residues 10 to 13 (Figure 1A,
bottom panel). Surprisingly, the current study found that
de novo DNA methylation of the Oct3/4 promoter during
RA-induced mESC differentiation was prevented only by
the mutation of the D905 in the non-cage portion of
histone H3 binding surface, while mutation of the cage
residues had no effect on the de novo DNA methylation of
Oct3/4 (Figures 3B and 3D). These interesting results indi-
cate that, while both the cage and non-cage residues are
involved in binding of K9-methylated histone H3, the non-
cage portion of the surface has a distinct function, which
presumably involves binding of a yet unknown protein that
mediates the role of G9a in de novo DNA methylation of
the Oct3/4 promoter. Although the percentage of DNA
methylation at day 8 RA seen in the KO (Figure 3B; 26%)
is higher than what was previously published by Epsztejn
and colleagues, the percentage of DNA methylation we
observed in the KO is consistently lower than both TT2
and +WT. We cannot rule out, however, that the pheno-
types observed in the G9a D905R mutant may be due to a
dominant gain of function rather than loss of function,
and further studies would be required to investigate
this. Importantly, our protein-protein interaction stud-
ies (Figures 4A and 4D) show that D905R mutant G9a
maintains its ability to interact with both GLP and
DNMT3A, therefore eliminating the possibility that the
impaired DNA methylation could be due to absence of
G9a-GLP complex formation or abrogated interaction
with DNMT3A. Although the Asp905 residue of the G9a
ankyrin domain is conserved in GLP, the phenotypes we
have observed indicate that the Asp905 surface of the G9a
ankyrin domain is non-redundant for its role in DNAmethylation and cannot be compensated by the presence
of wild-type GLP. This phenotype is in line with previous
studies regarding G9a/GLP global H3K9 methylation:
although both G9a and GLP conserved SET domains have
histone methyltransferase activity, only the G9a SET
domain (and not the GLP SET domain) catalytic function
is required for H3K9 global methylation [10].
Roles of the histone H3 binding surface and the DNMT3A
binding surface of G9a in de novo DNA methylation of
the Oct3/4 promoter
The ability of G9a ANK domain to bind DNMT3A pro-
vides a potential mechanism for the G9a-dependent de
novo DNA methylation of pluripotency genes such as
Oct3/4 during mESC differentiation; that is, G9a could
recruit DNMT3A to the Oct3/4 promoter. One way to
test this hypothesis is to identify the DNMT3A binding
surface of the G9a ANK domain and make point mutations
that eliminate DNMT3A binding. However, we found that
the G9a protein interaction surface that binds histone
H3 methylated at K9 is not involved in the binding of
DNMT3A by G9a. Thus, DNMT3A binds to a yet un-
defined surface of the G9a ANK domain. Furthermore,
since the D905R mutation in the histone H3 binding sur-
face eliminated G9a-dependent de novo DNA methylation
of the Oct 4 promoter without affecting the G9a-DNMT3A
interaction, our results indicate that the ability of G9a to
bind DNMT3A is not, by itself, sufficient to explain
G9a-dependent de novo DNA methylation. Rather, while
it still seems reasonable to assume that the binding of
DNMT3A is relevant for G9a-dependent de novo DNA
methylation, the ability of G9a to bind histone H3 or a
yet unknown protein through the binding surface that
includes D905 is also required.
A novel role for the ankyrin repeat domain in
G9a-dependent H3K9 methylation
Our studies have shown that G9a binding to H3K9me2
through the partial hydrophobic cage surface of the
ANK domain is not required for the maintenance of
global H3K9me2 levels. These results are surprising in
the light of the fact that it has been thought that G9a
binding to methyl-H3K9 might assist in propagating/
spreading this methyl mark across genomic regions and
thus might contribute to global cellular H3K9me2 levels.
Data presented here do not support this hypothesis and
leave open the question of the physiological relevance of
G9a ANK binding to methyl-H3K9. In contrast, the
D905R mutation not only prevented the G9a-dependent
de novo DNA methylation during RA-induced differenti-
ation of mESC, but also caused a dramatic reduction in
global cellular levels of H3K9me2 in the undifferentiated
mESC. Both of these phenotypes mirror that of mESC
lacking G9a entirely, indicating that this ANK surface is
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portantly, the impaired DNA methylation observed in the
G9a D905R ESCs is likely not due to defects in the forma-
tion of the G9a-GLP heteromeric complex since the
D905R G9a mutation does not abrogate the interaction
between G9a and GLP. Notably, although G9a-like protein
(GLP) also has a SET domain harboring H3K9 methyl-
transferase activity, it is not surprising that the deficient
H3K9me2 levels resulting from the G9a D905R mutation
cannot be compensated by GLP since it has previously
been shown that the catalytic activity of GLP is dispens-
able for H3K9 methylation in vivo [10].
As with de novo DNA methylation of the Oct3/4 pro-
moter, only the non-cage mutation D905R, but not any of
the cage mutations, reduced cellular H3K9me2 levels.
Thus, surprisingly these results indicate a critical role for
the ANK domain in establishing and/or maintaining the
global H3K9me2 levels. While the protein interaction by
the non-cage ANK surface that is required to support
H3K9 methylation by G9a has not been determined, the
fact that this non-cage surface interacts with residues 10
to 13 of histone H3 in the previously published X-ray
crystal structure suggests that this domain may somehow
cooperate with the SET domain in recognizing and/or
binding the H3 substrate for methylation by the SET
domain. Although we did not detect ANK binding to
unmethylated histone H3 in vitro [11], this does not rule
out the possibility that the non-cage ANK surface could
participate in an interaction with unmethylated histone
H3 in conjunction with some other protein or G9a
domain that binds unmethylated histone H3, such as the
G9a SET domain. Moreover, while the SET domain alone
is capable of methylating histone H3 in vitro, additional
experiments are required to test whether the ANK domain
and the non-cage histone H3 binding surface somehow
enhance the enzymatic function of G9a.
Roles of G9a in retinoic acid-induced differentiation of
mouse embryonic stem cells
Previous studies demonstrated that G9a is required for
mESC differentiation [15]. However, while de novo DNA
methylation of the Oct3/4 promoter fails to occur in G9a-
null mESC, Oct3/4 and Nanog gene expression is still
repressed in these cells after RA treatment, and other spe-
cific molecular drivers and markers of the differentiation
process that require G9a were not identified. By examin-
ing an expanded list of mESC-specific genes, we found
that, in addition to Oct3/4 and Nanog, G9a is also not
required for repression of Klf4, Esrrb and Dppa3 during
RA-induced differentiation. Therefore, other histone
modifiers (such as the PRC complex, for instance) and
chromatin-remodeling proteins are most likely involved
in the repression of these genes during ESC differenti-
ation. In contrast, we found that repression of SSEA-1is compromised by absence of G9a. Thus, G9a is required
selectively for repression of mESC-specific genes, and
SSEA-1 represents the first identified mESC-specific
protein marker that requires G9a for its repression dur-
ing RA-induced differentiation. This represents a valuable
marker of G9a-mediated ESC differentiation defects that
is both quantifiable and not lineage-specific. In addition,
we found that none of the point mutations in the ANK
surface that bind histone H3 prevented G9a-dependent
repression of SSEA-1 expression, indicating that G9a
domains outside of this histone H3-binding region of the
ANK domain are responsible for repression of SSEA-1 by
G9a during RA-induced differentiation. Furthermore, the
fact that cell lines expressing D905R mutant G9a have
compromised histone H3K9 and DNA methylation and
yet retain the ability to repress SSEA-1 expression in
response to RA suggests that histone H3K9 and DNA
methylation are not required for early steps of ESC dif-
ferentiation. However, these activities may be required
to achieve full terminal differentiation.Conclusions
Our data validate previous findings suggesting that the
G9a ANK domain is required for its role in de novo DNA
methylation of Oct3/4, and we define a specific residue
(Asp905) of the ANK domain as a key interaction surface
likely involved in protein-protein interactions critical for
G9a role in DNA methylation. Importantly, these findings
open exciting avenues for investigating the protein(s) that
interact(s) with G9a Asp905 in order to gain a better un-
derstanding of the precise molecular mechanisms of G9a
in de novo DNA methylation. In addition, our data show
that the G9a ANK domain methylhistone binding func-
tion is not required for its role in DNA methylation of
Oct3/4 during ESC differentiation. Altogether, the results
presented in this report advance our current understand-
ing of the G9a ANK domain structure and distinct func-
tional surfaces, revealing an unexpected role of the ANK
domain both in global histone H3K9 methylation in undif-
ferentiated ESCs and in de novo DNA methylation in a
manner independent of the interaction between G9a and
DNMT3A. Furthermore, these data collectively con-
tribute to us gaining better insights into the molecular
mechanisms (domains, surfaces and protein interac-
tions) of G9a involved in ESC self-renewal and differ-
entiation. Since epigenetic modifiers are increasingly
being valued as promising targets for cancer drugs, it
is important to investigate the role of G9a in ESC dif-
ferentiation as a clearer understanding of this process
would enable development of safer and more efficient re-
programming strategies for future therapeutic applications
of stem cells, and shed light on fundamental questions
concerning the establishment of cellular identity.
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Mouse embryonic stem cell culture
TT2 line and G9a-null ES cells were provided by Dr. Yoichi
Shinkai (Kyoto University, Kyoto, Japan). Undifferen-
tiated ES cells were maintained in Dulbecco’s Modi-
fied Eagle’s medium (DMEM, GIBCO) supplemented
with 13% (vol/vol) Stem Cell Qualified FBS (Gemini),
100 μM nonessential amino acids (GIBCO), 100 μM
2-mercaptoethanol (Sigma) and 103 U/ml leukemia
inhibitory factor (LIF; Millipore) at 37°C, and 5% CO2.
ESCs were seeded on gelatin (Millipore)-coated dishes.
For retinoic-acid (RA)-induced differentiation, cells were
cultured in the presence of 1 μM all-trans-RA (Sigma)
without LIF.
Generation of G9a-mutant embryonic stem cells
To generate stable cell lines expressing wild-type (WT)
or mutant G9a, the pHRCMVpuro-Sin8 vector contain-
ing a puromycin resistance cassette was introduced
simultaneously with a threefold excess molar ratio of
the G9a expression vector into the G9a-null ES cells by
either standard electroporation or by nucleofection.
Nucleofection (1 μg of plasmid DNA per 106 cells) was
performed using the Amaxa 4-D Nucleofector System
(Lonza) with the P3 Primary Cell 4-D Nucleofector X
Solution and the CG-104 program. Plasmid DNA used
for nucleofection was purified using the Endotoxin-free
Plasmid Maxiprep Kit (Qiagen) according to the manu-
facturer’s instructions. The stable transfectant clones
expressing mutant or WT G9a were selected in ESC
medium containing puromycin (1 μg/ml). All mutations
were confirmed in the selected cell clones by sequencing.
Plasmids
The following mammalian expression vectors were de-
scribed in previous publications: pSG5-FLAG encoding
full-length mouse G9a protein, including wild-type, anky-
rin mutants (D905R, E870R, W839A, E847A and W877A)
and SET mutant (H1166K) [11]; pcDNA3.1-mDNMT3A
[17]; and pHRCMVpuro-Sin8 [18]; pSG5-HA encoding
full length mouse G9a and a deletion mutant (ΔANK)
lacking the ankyrin repeat domain (amino acids 734 to
934) [19]. The GLP expression vector pSG5-FLAG GLP
(full-length, wild-type) was generated by PCR.
Antibodies used for immunoblot
The following antibodies were purchased and used for this
study: antibody to G9a (PP-A8620A-00) from R&D Biosys-
tems; antibody to DNMT1 (IMG-261A) from Imgenex;
antibody to HA (11867431001) from Roche; antibodies to
H3K9me2 (ab1220), DNMT3A (ab2850), and DNMT3B
(ab2851) from Abcam; antibodies to Oct3/4 (sc-8629),
and H3 (sc-10809) from Santa Cruz Biotechnology;
antibodies to FLAG (F1804), and GAPDH (G9545)from Sigma; antibodies to Sox2 (AB5603), and Nanog
(AB5731) from Millipore. Immunoblot detection was
performed by chemiluminescence using Super Signal
West Dura (Thermo Scientific) for proteins with low
expression levels and HyGLO (Denville Scientific) for all
other proteins according to the manufacturer’s instructions.
Immunoblots were performed on whole cell extracts (RIPA
buffer) or Acid Histone Extracts (http://www.abcam.com/
protocols/histone-extraction-protocol-for-western-blot).
Real-time RT-qPCR analysis
Total RNA was isolated using TRIzol (Invitrogen)
according to the manufacturer’s instructions. Reverse
transcription was performed by using iScript Advanced
cDNA Synthesis Kit for RT-qPCR (BioRad) according to
the manufacturer’s instructions by using 5 μg of total RNA
as template. qPCR amplification was performed on a Roche
LightCycler 480 by using SYBR Green I Master Mix
(Roche) and the following PCR primers: G9a.Fwd (5′-
AGCTTCGGAACAAAGAAGGAG -3′) and G9a.Rev
(5′- ACAGGGGATGGGTACATTCTC -3′); UBC.Fwd
(5′- CAGCCGTATATCTTCCCAGACT -3′) and UBC.
Rev (5′- CTCAGAGGGATGCCAGTAATCTA -3′); Oct3/
4.Fwd (5′- CTGAAGCAGAAGAGGATCACC -3′) and
Oct3/4.Rev (5′- GCCGCAGCTTACACATGTTC -3′);
Nanog.Fwd (5′- CAGCCTCCAGCAGATGCAAG -3′)
and Nanog.Rev (5′- AATCAGACCATTGCTAGTCTT
C -3′); Klf4.Fwd (5′- TCTCAAGGCACACCTGCGA
AC -3′) and Klf4.Rev (5′- GGTAGTGCCTGGTCAG
TTCATC -3′); Esrrb.Fwd (5′- CGCAAGAGCTACGA
GGACTG -3′) and Esrrb.Rev (5′- GGTAGCCAGAG
GCAATGTCC -3′); and Dppa3.Fwd (5′- AGTCTACG
GAACCGCATTGC -3′) and Dppa3.Rev (5′- GCTA
TAGGGTCTTTCAGCACCG -3′).
Bisulfite gDNA sequencing
Genomic DNA was isolated from ESC lines that were
untreated or treated with RA for 8 days using the DNeasy
Blood and Tissue Kit (Qiagen) according to the manufac-
turer’s instructions. Bisulfite treatment of the genomic
DNA was performed using the EZ DNA Methylation Kit
(Zymo Research) according to the manufacturer’s instruc-
tions. PCR was performed to amplify the Oct3/4 promoter
with the following primers: Oct3/4.bs.F (5′- TGGGTT
GAAATATTGGGTTTATTT -3′) and Oct3/4.bs.R (5′- C
TAAAACCAAATATCCAACCATA -3′). PCR products
were subcloned into pCR 2.1-TOPO vector using the
TOPO TA Cloning Kit (Invitrogen) and sequencing was
performed using the M13R primer that localizes to the
vector backbone.
Transfection co-immunoprecipitation
COS- 7 cells were transiently transfected by using Lipofec-
tamine 2000 (Invitrogen) with 5 μg of plasmid encoding
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tively, 4 μg of plasmid encoding GLP. At 72h after trans-
fection, cell extracts were prepared in RIPA buffer with
Nonidet P-40 and sodium deoxycholate replaced by
Triton X-100 (50 mM Tris- HCl (pH 8.0), 150 mM NaCl,
1% Triton X-100, and 1 mM EDTA). Antibodies used
were the same as those indicated for immunoblots.
Fluorescence-activated cell sorting analysis and cell sorting
Cells were trypsinized, washed once in PBS, and resus-
pended in PBS; dead cells were stained using the LIVE/
DEAD Fixable Dead Cell Stain Kit (Invitrogen) accord-
ing to the manufacturer’s instructions. Next, cells were
fixed in 2% paraformaldehyde (PFA) for 15 min at room
temperature, washed with PBS and stained with anti-
SSEA-1 mouse monoclonal IgM antibody (mc-480,
University of Iowa, Developmental Studies Hybridoma
Bank, 1:400) at 37°C for 20 min. After a PBS wash, the
cells were labeled with fluorescein isothiocyanate (FITC)-
conjugated goat anti-mouse IgM (Millipore, 1:200) for 15
min at 37°C. After one PBS wash, stained cells were resus-
pended in PBS containing 1% FBS and 3% BSA, and at
least 10,000 events of healthy cells were analyzed with a
CyAN Analyzer (Beckman Coulter) and FlowJo ver.10
software (Tree Star, Ashland, USA). Control cells were not
treated with primary antibody.
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